NMN Extends Lifespan Only in Female Mice, Sinclair Lab Finds
The Sinclair laboratory tested NMN supplementation in mice from mid‑life (13 months) to death. Females showed a median lifespan increase of 8.5% and a maximum increase of 7.9%, while males derived no longevity benefit. NMN delayed frailty by 31 aging markers in both sexes.
Mice received NMN at a dose 2–3 times the clinical level — roughly ~3 g/day for a 70 kg human — throughout the treatment period. The compound equally improved markers of physical frailty regardless of sex.
NMN triggered a >10‑fold rise in the gut bacterium *Anaerotruncus colihominis*, which in vitro converted labeled NMN to NAD+ within 20 h. This microbial activity accounts for the frailty reduction and partly explains the early‑life mortality protection seen in males.
In females, hepatic and muscular genes governing mitochondrial function and DNA repair were upregulated, resembling calorie‑restriction benefits. Males exhibited suppressed mitochondrial genes and heightened inflammatory pathways driven by CD38 and PARP, which consume NAD+. The findings are detailed in the препринт лаборатории Синклера от 21 сентября, which notes Sinclair’s conflict of interest as co‑founder of MetroBiotech. Authors propose pairing NMN with CD38 or PARP blockers to extend the longevity benefit to males.
🔗 Read original →
Researchsquare
An error has occurred
Research Square is a preprint platform that makes research communication faster, fairer, and more useful.
September 23, 2026 10
